Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COBRA: Carfilzomib + lenalidomide + dexamethasone versus bortezomib + lenalidomide + dexamethasone in newly diagnosed multiple myeloma
2018-004031-68Phase 3Active
- Sponsor
- Polish Myeloma Consortium
- Start
- Aug 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of carfilzomib, bortezomib, lenalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Polish Myeloma Consortium. Primary endpoints: MRD-negative complete response at 12 months and Progression-free survival (PFS). Started Aug 2019; status: active.
02
Drugs
carfilzomibbortezomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2018-004031-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004031-68.